多剂量聚乙二醇干扰素α-2b在肾功能不全患者中的药代动力学特征

黄承杰

黄承杰. 多剂量聚乙二醇干扰素α-2b在肾功能不全患者中的药代动力学特征[J]. 实用临床医药杂志, 2012, (17): 126-127,132.
引用本文: 黄承杰. 多剂量聚乙二醇干扰素α-2b在肾功能不全患者中的药代动力学特征[J]. 实用临床医药杂志, 2012, (17): 126-127,132.

多剂量聚乙二醇干扰素α-2b在肾功能不全患者中的药代动力学特征

详细信息
  • 中图分类号: R692

  • 摘要: 丙型肝炎病毒(HCV)感染是一种常见的引起肝脏疾病的重要原因.清除干扰素的主要机制是经肾脏代谢,对以干扰素为基础治疗的终末期肾病患者来讲,合适的干扰素剂量选择很重要.单剂量药代动力学研究表明,肾功能不全患者肾清除的聚乙二醇干扰素α-2b (PEG IFN α 2b)药物的总清除率仅30%的[1],表明可能存在其他更占优势的药物清除路线存在.通过肾脏清除药物的比例较低,可能原因是大的PEG-干扰素分子不易透过.
  • Gupta S K, Pittenger A L, Swan S K. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction [J]. Journal of Clinical Pharmacology, 2002, (10):1109.
    Sood A, Midha V, Hissar S. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3:an Indian experience [J]. Journal of Gastroenterology and Hepatology, 2008(2):203.
    谭英征, 陈双华, 傅京力. 聚乙二醇干扰素α-2a和重组人干扰素α-2b治疗慢性丙肝临床疗效观察 [J]. 实用临床医药杂志, 2010, (15):75.doi: 10.3969/j.issn.1672-2353.2010.15.027.
    刘志荣, 王磊, 吕卉. 干扰素和利巴韦林联合用药对慢性丙型肝炎患者肝组织中α-SMA、TIMP-1的影响 [J]. 山东大学学报(医学版), 2007(4):365.doi: 10.3969/j.issn.1671-7554.2007.04.011.
    Czock D, Rasche FM. Dose adjustment of ciprofloxacin in renal failure:reduce the dose or prolong the administration interval [J]. European Journal of medical Research, 2005(4):145.
    Fischer KG. Hirudin in renal insufficiency [J]. Seminars in Thrombosis and Hemostasis, 2002(5):467.
    Anderson GD, Odegard PS. Pharmacokinetics of estrogen and progesterone in chronic kidney disease [J]. ADVANCES IN CHRONIC KIDNEY DISEASE, 2004(4):357.
    Carlson K, Hjorth M, Knudsen L M. Toxicity in standard melphalan prednisone therapy among myeloma patients with renal failure-a retrospective analysis and recommendations for dose adjustment [J]. British Journal of Haematology, 2005(5):631.
    Poordad F F, Fabrizi F, Martin P. Hepatitis C infection associated with renal disease and chronic renal failure [J]. Seminars in Liver Disease, 2004, (Suppl 2):69.
    Bex A, Mallo H, Kerst M. A phase Ⅱ study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor [J]. Cancer Immunology Immunotherapy, 2005(7):713.
计量
  • 文章访问数:  162
  • HTML全文浏览量:  28
  • PDF下载量:  6
  • 被引次数: 0
出版历程
  • 发布日期:  2013-01-15

目录

    /

    返回文章
    返回